• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Indian High Court Clears $4 BN Sun-Ranbaxy Merger


March 10, 2015.

The Pujnab & Haryana High Court in India has cleared the $4-billion merger between Sun Pharmaceutical Industries and Ranbaxy Laboratories, which will make Sun the world’s fifth-largest generic drug maker, Business Standard (BS)(India) reports. 

The buyout is valued at $3.2 billion, but with Ranbaxy’s debts of $800 million, the overall transaction value comes to $4 bn, adds the report.

Japan’s Daiichi Sankyo acquired a 63.9 per cent stake in Ranbaxy for $4.2 bn in 2008, but, the BS report adds, "the value of its investment has since halved, as Daiichi hasn’t been able to ensure compliance with norms at Ranbaxy’s factories supplying drugs to the US."

Related Videos